AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00403364
Drug: Placebo amoxicillin pantoprazole clarithromycin tinidazole
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02600806
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
Trial: NCT01924819
Drug: Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)
Trial: NCT04042974
Drug: vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT04042974
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT03656926
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
Trial: NCT00923195
Drug: MART-1: 26-35(27L) Peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Trial: NCT00923195
Drug: gp100:154-162 Peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Trial: NCT00923195
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
Trial: NCT01613131
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical, .06%, Applied once daily for 50 days.
Trial: NCT01613131
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel, Applied once daily for 50 days, Placebo comparator.
Trial: NCT02516631
Drug: Angusta™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Angusta™ (25 µg) given every 2 hours
Trial: NCT02516631
Drug: Cytotec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
Trial: NCT02516631
Drug: Angusta™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Angusta™ 25 µg given every 4 hours
Trial: NCT02516631
Drug: Cytotec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
Trial: NCT02516631
Drug: Angusta™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
Trial: NCT02516631
Drug: Cytotec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
Trial: NCT01526122
Drug: G0041(75/100mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
Trial: NCT03739840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided matching padsevonil.
Trial: NCT00830063
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 1000 mg daily for 16 weeks
Trial: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg po daily
Trial: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg po monthly on a single day
Trial: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg po monthly over 2 consecutive days
Trial: NCT00048061
Drug: Ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly
Trial: NCT00380913
Drug: Cesamet™ (nabilone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01269593
Drug: PET Imaging using 124 IPUH71
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
Trial: NCT01795703
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Trial: NCT00416403
Drug: fluvastatin sodium
RxNorm normalized name: Fluvastatin Sodium
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03165890
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT02370784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral drug of similar appearance to atorvastatin
Trial: NCT02140164
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
Trial: NCT00689403
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release capsules, oral single doses
Trial: NCT01828515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01828515
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
Trial: NCT00004686
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00136019
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01236014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo \& standard of care
Trial: NCT03053271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
Trial: NCT00666796
Drug: Placebo ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Trial: NCT00666796
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
Trial: NCT00666796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
Trial: NCT03435614
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
Trial: NCT02594332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02331875
Drug: IPH2201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
Trial: NCT00276913
Drug: STA-5312
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00558155
Drug: peptisorb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard isocaloric eteral diet (1 ml = 1 kcal)
Trial: NCT00558155
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Trial: NCT00558155
Drug: Omegaven, Dipeptiven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
Trial: NCT03029741
Drug: AZD0284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
Trial: NCT03029741
Drug: [14C]AZD0284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
Trial: NCT04455243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered in the same schedule and volume as NAC
Trial: NCT04541290
Drug: Protopic 0.1 % Topical Ointment
RxNorm normalized name: Protopic 0.1 % Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
Trial: NCT01033526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
Trial: NCT00884325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet taken orally at night for 28 days
Trial: NCT01540825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution
Trial: NCT03800693
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03800693
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00276705
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00276705
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02569827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q6H for 5 days
Trial: NCT02071381
Drug: DW1030 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248337
Drug: Colon preparation for colonoscopy
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon cleansing prior to perform colonoscopy
Trial: NCT00002747
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04255927
Drug: Coated Vicryl plus
RxNorm normalized name: VICRYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicryl plus (Coated Polyglactin 910 with Triclosan)
Trial: NCT04255927
Drug: Coated vicryl
RxNorm normalized name: VICRYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicryl (Coated Polyglactin 910 without Triclosan)
Trial: NCT02288247
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02288247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04537819
Drug: Imupret in addition to local NAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
Trial: NCT04537819
Drug: Local NAID (Benzydamin)
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
Trial: NCT00004187
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00877474
Drug: PM01183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
Trial: NCT01100736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
Trial: NCT02162849
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
Trial: NCT02162849
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
Trial: NCT02342366
Drug: GHB 35 mg/kg p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 35 mg/kg p.o.
Trial: NCT02342366
Drug: GHB 20 mg/kg p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 20 mg/kg p.o.
Trial: NCT04663737
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
Trial: NCT01364623
Drug: Low dose testosterone nasal gel, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose testosterone nasal gel, single dose
Trial: NCT01364623
Drug: Medium dose testosterone nasal gel, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose testosterone nasal gel, single dose
Trial: NCT01364623
Drug: High dose testosterone nasal gel, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose testosterone nasal gel, single dose
Trial: NCT01364623
Drug: Medium dose testosterone nasal gel, multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose testosterone nasal gel, multiple dose
Trial: NCT05673772
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
Trial: NCT03587662
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03587662
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04148183
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We add Placebo, treatment was administered for 8 weeks
Trial: NCT02057341
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT03875391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo nasal spray
Trial: NCT03543033
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
Trial: NCT03627182
Drug: CKD-501 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Trial: NCT03627182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study).
Trial: NCT00397839
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate orally (tablet) at a dose of 150 mg once per month
Trial: NCT00397839
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally (tablet) at a dose of 150 mg once per month
Trial: NCT03809923
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Trial: NCT01712321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
Trial: NCT01353508
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg and 400 mg tablets
Trial: NCT00670358
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00670358
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00613106
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
Trial: NCT02952040
Drug: ASP1517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT01497145
Drug: KRN321
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03586830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Trial: NCT03872700
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Citrate
Trial: NCT01284595
Drug: [14C] AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 160 mg oral dose administered on Day 1
Trial: NCT03204786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray
Trial: NCT04164069
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV